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ABSTRACT Infectious bronchitis (IB), caused by in-
fectious bronchitis virus (IBV), account for severe eco-
nomic losses in the poultry industry. The continuous
emergence of a multitude of IBV variants poses many
challenges for its diagnosis and control, and live atten-
uated vaccines, despite their routine use, still plays a
significant role in driving IBV evolution, further com-
plicating the epidemiological scenario. Unfortunately,
the impact of different vaccination strategies on IB
control, epidemiology, and diagnosis has rarely been
investigated.
This work presents the results of a large-scale diag-
nostic survey performed in Poland to study IBV molec-
ular epidemiology and how vaccination may affect the
viral circulation in the field. To this purpose, 589 sam-
ples were collected between May 2017 and January
2019, tested by reverse transcription-PCR for IBV and
sequenced. Vaccine and field strains were discriminated
based on genetic and anamnestic information.
The most commonly detected lineages were 793B
(79%) and variant 2 (17.4%), with sporadic detections
of QX, Mass, and D274-like strains. Most of the de-
tected strains had a vaccine origin: 46.3% matched one
of the applied vaccines, while 36.5% were genetically re-
lated to vaccines not implemented in the respective pro-
tocol. Besides their practical value for the proper plan-
ning of vaccination protocols in Poland, these results
suggest that only a fraction (17.2%) of the circulating
strains are field ones, imposing a careful assessment of
the actual IBV field menaces. Moreover, phenomena
like vaccine spreading and persistence seem to occur
commonly, stressing the need to further study the epi-
demiological consequences of the extensive use of live
vaccines.
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INTRODUCTION
Infectious bronchitis virus (IBV) is a worldwide dis-
tributed enveloped ssRNA+ virus that belongs to the
species Avian coronavirus, genus Gammacoronavirus,
family Coronaviridae. It is the causative agent of infec-
tious bronchitis (IB), a highly contagious disease that
affects the respiratory, reproductive, and renal systems
of chickens of all ages and types (De Wit et al., 2011).
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Its economic impact on the poultry industry is second
only to highly pathogenic avian influenza viruses, and
IB is estimated to account for the third highest losses
among all livestock diseases (TAFS-Forum, 2011).
IBV control relies on routine vaccination, along with
proper biosecurity measures (De Wit et al., 2011). How-
ever, this approach is hindered by the high genetic vari-
ability of the virus, due to both mutation and recom-
bination events, resulting in the continuous emergence
of new variants with generally poor cross-protection
(Bande et al., 2015). Multiple vaccines, either live at-
tenuated or inactivated, are usually combined in the
attempt to obtain a proper protection: the protection
against a certain variant may be achieved by admin-
istering either a single vaccination based on a strain
of the same lineage (homologous vaccination) or multi-
ple vaccines based on different lineages to broaden the
protection spectrum, following the so-called “protecto-
type” concept (heterologous vaccination) (Cook et al.,
1999; Jordan, 2017).
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Despite essential to a proper control of the disease,
the extensive use of IBV vaccines has some well-known
drawbacks. The impact of vaccination protocols on cir-
culating strains, which include field, live-vaccine and
also “vaccine-derived” strains, proved remarkable and
some lineages even disappeared after the discontinuance
of homologous vaccination (Franzo et al., 2014, 2016).
Live vaccine strains may spread to unvaccinated flocks,
regain virulence because of rolling-like reactions or re-
combine with other circulating strains, possibly result-
ing in the emergence of new variants (Matthijs et al.,
2008; Jackwood and Lee, 2017; Moreno et al., 2017). In
addition, their use has been suggested to increase IBV
mutation rate by applying an immunologic pressure on
the field population (Jackwood et al., 2012). The per-
sistence of vaccine strains also complicates IBV diag-
nosis, since many detected strains are usually closely
related or identical to the applied vaccines (Jackwood
and Lee, 2017). Therefore, clearly vaccination protocols
must be taken into account to delineate an accurate
picture of IBV epidemiological context within a given
area.
In this work, a large scale diagnostic survey was
conducted over a 20 mo timespan in Poland, the Eu-
ropean leading country in poultry meat production
(http://www.fao.org/faostat), to obtain updated infor-
mation about circulating strains and commonly admin-
istered vaccines and study how vaccination choices may
affect IBV epidemiology.
MATERIALS AND METHODS
Samples were collected from broiler farms in Poland
and consisted of pools of 10 swabs, either tracheal or
cloacal. Information about collection date, birds age,
applied vaccination, and presence of symptoms was also
recorded. Pooled swabs were eluted in 2 mL of 1%
PBS solution, and RNA extraction was performed with
High Pure RNA Isolation Kit (ROCHE, Basel, CH).
Samples were tested for IBV by RT-PCR using Super-
Script III One-Step RT-PCR System with Platinum
TaqDNA Polymerase kit (Thermo Fisher, Waltham,
MA), amplifying a 464 bp hyper-variable region of the
S1 gene with XCE1+ and XCE2- primers described by
Cavanagh et al. (1999). Positive samples were Sanger-
sequenced using the same primers. The chromatograms
were evaluated with FinchTV software (http://www.
geospiza.com) and consensus sequences were assembled
with CromasPRO 1.5 software (http://technelysium.
com.au/wp/chromaspro/). Sequences were then aligned
using the MUSCLE method implemented in MEGA7
(Kumar et al., 2016) and analyzed for strain genotyp-
ization and characterization by comparing them to a
database including a set of commonly applied vaccine
strains and Valastro et al. (2016) reference sequences.
The detected strains were classified as vaccines
when they were identical or closely related (p-distance
<0.01) to one of the administered vaccine (Worthington
et al., 2008). The other strains were considered: a field
strain, if the p-distance was higher than 0.01 compared
to known vaccines or a vaccine-derived one, if they were
closely related (p-distance <0.01) to known vaccines
not matching the ones applied in the farm.
Pearson’s Chi-squared test with Yates’ continuity
correction was applied to infer non-casual distributions
of categorical variables. All statistical analyses were
performed using R software, setting the significance
level to P < 0.05.
RESULTS
A total of 589 samples were collected during the pe-
riod from May 2017 to January 2019. Samples consisted
of tracheal (5.3%) or cloacal (44.5%) swabs or a com-
bination of both (50.2%); mean age at sampling was
35.7 D of age (doa). In 26 cases, respiratory and/or
renal symptoms possibly due to IB were reported; in
all the other cases, samples were taken for IBV routine
monitoring.
More than 70 different vaccination protocols against
IBV were implemented, based solely on live attenuated
vaccines and differing in applied vaccines and/or ad-
ministration schedule. 83.4% of these were based on the
combined administration of at least 2 IBV vaccines at
1 doa; 2 or more vaccines were administered at differ-
ent time points in 9.7% of the cases, while 6.6% of the
protocols relied on a single IBV vaccine. No IBV vacci-
nation was performed in 2 cases. The most frequently
adopted protocol was based on Mass (lineage GI-I) and
793B (lineage GI-13) vaccines administered at day 1
(225 out of 589 samples, 38.2%). Mass vaccines were
implemented in 575 cases (97.6%), while 490 flocks were
vaccinated with 793B ones (83.2%): in detail, vaccines
based on 4/91, 1/96, and CR88 strains were applied 101
(17.1%), 352 (59.8%) and 37 (6.3%) times, respectively.
Other adopted vaccines were based on variant 2, D274,
and QX strains, and were implemented in 98 (16.6%),
57 (9.7%), and 9 (1.5%) farms respectively.
A total of 501 samples (85%) tested positive for IBV,
and 482 high-quality sequences were retrieved. The se-
quencing results are presented in Table 1. 793B was the
most frequently detected one (382 out of 482 sequences;
79.3%): 224 of the 793B sequences (58.6%) were identi-
cal or closely related (i.e., less than 1% genetic distance)
to strain 4/91, 125 (32.7%) to strain 1/96 and 5 (1%)
to strain CR88, while 28 strains (7.3%) were classified
as 793B field strains. A total of 84 strains (17.4%) be-
longed to variant (lineage GI-23), while QX (GI-19),
Mass (GI-I), and D274-like (GI-12) were identified in
9 (1.9%), 5 (1%), and 2 (0.4%) samples, respectively.
The remaining 88 samples were negative, including the
two samples taken from unvaccinated flocks. Among the
different matrixes (tracheal and cloacal swabs or a com-
bination of both), no significant differences in terms of
frequency of the identified lineages were detected.
When the correspondence between vaccination strat-
egy and obtained sequence was evaluated, one of the
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Table 1. Sequencing results characterized by lineage and vaccine or field origin. Strains were classified as vaccine strains, when
genetically identical or closely related (p-distance < 0.01) to one of the applied vaccines, vaccine-derived strains, when genetically
identical or closely related to a vaccine not administered in the respective flock, or field strains when not closely related (p-distance










G1–1 (Mass) 5 5 / /
G1–12 (D274-like) 2 2 / /
1/96 117 1/96 8
G1–13 (793B) 382 4/91 65 4/91 159 28
CR88 5 CR88 /
G1–19 (QX) 9 3 2 4
G1–23 (Variant 2) 84 26 7 51
Total 482 223 176 83
applied vaccines was detected in 46.3% (223/482) of
IBV positive samples. As for the remaining 259 strains,
176 (36.5%) were classified as vaccine-derived and 83
(17.2%) as field ones. In all 93.6% of 1/96-like detec-
tions occurred when a homologous vaccine was applied,
as opposed to 4/91-like (27.4%), Variant 2 (30.9%)
and QX (33.3%) detections. All Mass, CR88-like, and
D274 detections occurred when a homologous vaccina-
tion was implemented. Regarding the 83 field strains,
28 were classified as 793B, 4 as QX, and 51 as vari-
ant 2. The frequency of vaccine and field strains detec-
tions showed no significant differences among different
matrixes.
Considering only the 26 samples taken from symp-
tomatic flocks, 5 of the detected strains (19.2%) were
vaccines, 10 (38.4%) were classified as 4/91-like vaccine-
derived strains, and 11 (42.4%) were field ones. Among
the field strains, 7 were variant 2, 3 793B, and 1 QX.
DISCUSSION
The present study depicts a complex and intricate
epidemiological scenario, entangled by the simultaneous
circulation of field and vaccine strains, the latter being
the vast majority (82.8%). Remarkably, the evaluation
of the applied vaccination strategies revealed a surpris-
ingly intricate scenario, involving more than 70 different
protocols. The most frequent approach for combining
multiple IBV vaccines was to apply them simultane-
ously at 1 doa (83.4%). Despite the fact that separate
administrations of 2 or more IBV vaccines are tradi-
tionally considered more effective, possibly because of
the booster effect and respiratory epithelium recovery
between the applications (Cook et al., 1999; De Wit
et al., 2010), nowadays the combined administration
at 1 doa is commonly adopted in different countries
(Franzo et al., 2016; Jordan, 2017). In fact, hatchery
vaccination allows a higher standardization and broader
vaccine coverage than field vaccination (Franzo et al.,
2016) and at the same time eliminates the need of a
second administration, thus reducing the costs. The
present study also confirms this trend in Poland. Unfor-
tunately, the limited number of farms applying separate
vaccinations and the negligible number of symptomatic
flocks prevented the comparison of the efficacy of the
2 strategies. Nonetheless, the relatively low amount of
detected field strains (17.2%) and clinical outbreaks
(4.4%) seems to support the efficacy of widespread vac-
cination, regardless of the adopted strategy.
The greater part of the obtained sequences (79.3%)
was classified as 793B. Since 92.7% of them were of vac-
cine origin (4/91, 1/96, or CR88-like), the high preva-
lence of this lineage may be due to the vast application
of 793B vaccines, administered in 83.2% of the sampled
flocks. Interestingly, although Mass vaccines were pro-
vided even more frequently (97.6% of the times) and
often together with the 793B ones, Mass strains were
only found in 5 samples. The more frequent detection of
793B strains may be explained by 793B vaccines per-
sisting longer and/or reaching higher titers than the
Mass ones in field conditions (Cavanagh et al., 1999;
Tucciarone et al., 2018).
The other detected strains were classified as D274-
like, QX, and variant 2 strains. While D274-like strains
were found only twice in D274-vaccinated flocks, the
relevance of QX and variant 2 as field lineages is
well known. QX was detected for the first time in
China in 1996 and, as of today, it is probably the
most important field lineage in both Asia and Eu-
rope (Franzo et al., 2017a). It is responsible for
severe economic losses, causing respiratory and re-
nal symptoms and is also associated to the “false-
layer syndrome” in breeding and laying hens (De
Wit et al., 2011). Variant 2 is an emerging lineage
that, after staying confined to Israel for nearly a
decade following its first detection in 1998 (Callison
et al., 2001), spread firstly to the whole Middle
East, then to Turkey and Eastern Europe (Ganapa-
thy et al., 2015; Yilmaz et al., 2016; Franzo et al.,
2017b). Poland is the first European country where this
nephropathogenic variant was detected in 2015, and the
threat of its remarkable clinical impact has elicited the
introduction of a homologous vaccine (Lisowska et al.,
2017). Of the 9 QX detections, 3 vaccine strains were
detected in QX-vaccinated flocks, 2 were labeled as
vaccine-derived strains, and 4 as field ones. Variant 2
strains were detected in 84 samples: 26 were classified
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as vaccine, 8 as vaccine-derived, and 51 as field strains,
highlighting the persistence of this lineage in Poland
in the considered period. Therefore, the relevance of
these lineages in Poland appears to be modest, espe-
cially from a clinical perspective.
The large number of vaccine-derived strains (36.5% of
the detections) certainly raises some questions on the
capability of live vaccines to spread and persist, even
in farms where they are not adopted. Notably, 89.3%
of the detected vaccine-derived strains were 4/91-like
ones. In all 72.8% of the 4/91 detections occurred in
farms not adopting this vaccine, as opposed to 6.4% and
none of the 1/96 and CR88 detections: the significant
difference (P-value < 0.001) suggests a higher spreading
capability of the 4/91 vaccine compared to the 1/96-
based one, as previously reported (Franzo et al., 2014;
Pellattiero et al., 2018). Several causes could justify the
observed scenario, including a higher vaccine shedding
or longer persistence. Although unlikely, an underling
association between farm management and employed
vaccine, favoring the dispersion of specific vaccines, can-
not totally be excluded.
A possible explanation for the several discrepancies
between sequencing results and administered vaccines
might reside in the old age of the sampled birds. When
Mass and/or 793B vaccines are administered at 1 doa,
their titers are expected to peak approximatively at 10
to 14 doa, way before the average age of sampling in
this study (i.e., 35.7 doa), and then gradually decrease
(Tucciarone et al., 2018). This was confirmed by the
fact that one of the applied vaccines was detected 90%
of the times when birds were sampled before 16 doa,
as opposed to 45.6% of the times when they had 16 or
more doa. Therefore, it seems plausible that field and
vaccine-derived strains could penetrate in a farm after
the applied vaccines decline. Since most of discordances
between applied and detected vaccines occurred within
the 793B lineage, further efforts should be directed to
investigate the causes behind the limited protection
from infection even between homologous vaccines.
A strain not matching with any of the applied vac-
cines was detected in 73.3% of the symptomatic flocks,
as opposed to 46.3% in healthy flocks: the difference was
statistically significant (P-value = 0.032), thus support-
ing the possible causative role of the detected strains.
These strains were classified as 793B (13 detections,
of which 10 4/91-like vaccine-derived strains and 3 field
ones), Variant 2 (7 field strains) and QX (1 field strain).
In fact, while a link between symptoms and detections
of variant 2, QX, and 793B field strains can easily be
justified, the detection of 4/91-like strains in symp-
tomatic animals should draw attention to the possible
pathogenic role of vaccine-derived strains. The number
of vaccine-derived and field strains detected in symp-
tomatic flocks is substantially equal, and this should
stimulate a discussion on the advantages and disad-
vantages of a widespread, poorly-planned vaccine ap-
plication. However, these findings are not conclusive.
Even when overt clinical signs are observed, it is prac-
tically impossible to certainly determine based solely
on molecular analyses if the detected strain is a truly
pathogenic one or a virus of vaccine origin inciden-
tally detected in presence of other causative pathogens
(Jackwood and Lee, 2017). Moreover, no genetic mark-
ers are currently known to consistently distinguish be-
tween vaccine and field strains (Jackwood and Lee,
2017). Although a combination of phylogenetic and epi-
demiological criteria was adopted in the present study
to confidently classify sequenced strains, the presence
of some misclassification due to the circulation of ac-
tual field strains closely related (at least in the con-
sidered genomic region) to vaccine viruses cannot be
excluded and will deserve more extensive evaluations,
possibly based on the entire S1 gene sequence. Nonethe-
less, besides the potential direct cost of vaccine-induced
clinical signs, the endemic circulation of vaccine strains
has other effects on IBV epidemiology, increasing the
likelihood of recombination events and the genesis of
strains with unpredictable features. As demonstrated
in the present study, their persistence also severely
complicates the interpretation of the epidemiological
scenario and thus the planning of effective control
strategies.
According to the obtained results, the impact of IBV
on poultry health in Poland appears scaled down, likely
because of the widespread vaccination. Field strains
(belonging to lineages variant 2, 793B, and QX) ac-
counted for a limited part of the total detected strains
and were seldom detected in presence of symptoms. To
cope with the relatively limited IBV challenge, an out-
standing high number of different vaccination protocols
were observed. This could be imputable to the organi-
zation of the poultry industry in Poland, where vertical
integration is quite loose, allowing a certain plasticity
of the managerial decisions on vaccination mainly based
on the farm history and requirements.
This work may be of great practical help, providing
updated information about the strains actually circu-
lating in Poland. Given the extreme heterogeneity of
vaccination plans applied in this country, an effort to
homogenize them would be hugely beneficial and facili-
tate the understanding of IBV epidemiology, allowing a
more efficient use of limited resources, a maximization
of cost-benefit ratio and farm profitability and a reduc-
tion of the consequences that uncontrolled circulation
of vaccine-derived strains circulation can cause on IBV
diagnostics and evolution.
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